# RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

> **NCT05134519** · PHASE2 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)

## Key facts

- **NCT ID:** NCT05134519
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-26
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05134519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05134519, "RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05134519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*